CER-1236
Phase 1Small molecule
CER-1236 is one of 24 small molecule programs targeting AML. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
28 competitors in AML
#DrugCompanyPhaseTrials
1Fludara
SanofiApproved
Cytosar
TevaPhase 3
Venclexta
AbbViePhase 3
Idamycin
PfizerPhase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Homoharringtonine
Ascentage Pharma Group Inc.Phase 3
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Tibsovo
SServier
Phase 2
Xospata
AstellasPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CER-1236. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CCERo Therapeutics Holdings, Inc.